Affiliation: The First Affiliated Hospital
- Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH studyShukui Qin
People s Liberation Army Cancer Center, Bayi hospital, Nanjing, People s Republic of China Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People s Republic of China Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People s Republic of China Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People s Republic of China Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People s Republic of China Medical Affairs, Sanofi China, Shanghai, People s Republic of China Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People s Republic of China Department of Hepatobiliary Surgery, the First Affiliated Hospital of Sun Yat Sen University, Guangzhou, People s Republic of China Department of Interventional Radiology, Sun Yat sen University Cancer Hospital, Guangzhou, People s Republic of China Department of Medical Oncology, Wuhan Union Hospital, Hubei, People s Republic of China Department of Medical Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China LinKou Medical Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China Department of Hepatobiliary Surgery, Japan
Oncologist 19:1169-78. 2014..We present the results of this study in Chinese patients...
- Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b studyJun Guo
Peking University Cancer Hospital and Institute, No 52, Fucheng Road, Beijing 100142, China
BMC Cancer 13:136. 2013..This phase 1b study was designed to further evaluate the safety and efficacy of everolimus in VEGFr-TKI-refractory Chinese patients with mRCC...
- Defining the critical hurdles in cancer immunotherapyBernard A Fox
Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
J Transl Med 9:214. 2011..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
- Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cellsQiong Wu
Department of Medical Oncology, Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
J Hematol Oncol 3:43. 2010..In the present study, the effect of lobaplatin was assessed in five HCC cell lines and the underlying molecular mechanisms in terms of cell cycle kinetics were explored...
- Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinomaWinnie Yeo
Prince of Wales Hospital, Shatin, Hong Kong
BMC Cancer 10:620. 2010..Finally, Asian nations must be urged to participate in clinical trials, many of which are ongoing, to advance new treatment options in this challenging disease...
- Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patientsHaiqing Hua
Bayi Post doctoral Workstation, Nanjing General Hospital of Nanjing Military Command Post Doctoral Research Station, Nanjing, China
Asian Pac J Cancer Prev 12:61-5. 2011..Pharmacokinetics after As₂O₃ injection into patients with a primary hepatocarcinoma (PHC) were therefore investigated...
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III TrialCalin Cainap
Calin Cainap, Institute of Oncology, Cluj Napoca, Romania Shukui Qin, Chinese People s Liberation Army Cancer Center, Bayi hospital, Beijing Hongming Pan, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou Ying Cheng, Tumor Hospital of Jilin Province, Changchun, People s Republic of China Wen Tsung Huang, Chi Mei Medical Center, Liouying Pei Jer Chen, National Taiwan University Hospital, Taipei, Taiwan, Republic of China Ik Joo Chung, Chonnam National University, Hwasun Hospital, Hwasun, Jeollonam do Yoon Koo Kang, Asan Medical Center, University of Ulsan, Seoul, Republic of Korea Masatoshi Kudo, Kinki University, Osaka, Japan Han Chong Toh, National Cancer Centre, Singapore, Singapore Vera Gorbunova, Russian Academy of Medical Sciences, Moscow, Russia Ferry A L M Eskens, Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands Jiang Qian, Center for Survey Research
J Clin Oncol 33:172-9. 2015..This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy...
- Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from AsiaShukui Qin
Shukui Qin, People s Liberation Army Cancer Centre, Bayi hospital, Nanjing Yuxian Bai, Third Affiliated Hospital, Harbin Medical University, Harbin Jia Fan, Zhongshan Hospital, Fudan University Yu Zhou, sanofi aventis Asia, Shanghai Yan Sun, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China Ho Yeong Lim and Won Ki Kang, Samsung Medical Centre Won Ki Kang, Sungkyunkwan University School of Medicine Jee Hyun Lee, sanofi aventis Korea, Seoul, Korea Sumitra Thongprasert, Chiang Mai University, Chiang Mai Vajarabhongsa Bhudhisawasdi, Khon Kaen University, Khon Kaen, Thailand Yee Chao, Taipei Veterans General Hospital, Taipei and Tsai Shen Yang, Chang Gung Memorial Hospital, Linkou Medical Center, Chang Gung University, Taoyuan, Taiwan
J Clin Oncol 31:3501-8. 2013....
- Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trialAnn Lii Cheng
Ann Lii Cheng, National Taiwan University Hospital, Taipei Deng Yn Lin, Chang Gung Memorial Hospital, Chang Gung University, Guishan Township, Taiwan, Republic of China Yoon Koo Kang, Asan Medical Center, University of Ulsan College of Medicine Hyun Cheol Chung, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul Joong Won Park, National Cancer Center, Goyang, Republic of Korea Masatoshi Kudo, Kinki University Hospital, Osaka Masao Omata, Yamanashi Prefecture Central Hospital, Kofu, Yamanashi, Japan Shukui Qin, Nanjing Bayi Hospital, Nanjing Xiangqun Song, Tumor Hospital of Guangxi Zhuang Autonomous Region, Nanning Jianming Xu, Beijing 307 Hospital Cancer Centre, Beijing, People s Republic of China Guido Poggi, Istituto di Ricovero e Cura a Carattere Scientifico Fondazione Maugeri, Pavia Silvana Lanzalone, Maria Jose Lechuga, Pfizer Italia Srl, Milan, Italy Susan Pitman Lowenthal, Pfizer Oncology, New York, Taiwan University College of Medicine
J Clin Oncol 31:4067-75. 2013..Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer...